Diagnostic research criteria for Alzheimer’s disease support the use of biomarkers in the cerebrospinal fluid (CSF) to improve the accuracy of the prognosis regarding progression to dementia for people with mild cognitive impairment (MCI).
Objective:
The aim of this study was to estimate the potential incremental cost-effectiveness ratio of adding CSF biomarker testing to the standard diagnostic workup to determine the prognosis for patients with MCI.
Methods:
In an early technology assessment, a mathematical simulation model was built, using available evidence on added prognostic value as well as expert opinion to estimate the incremental costs and quality-adjusted life years (QALYs) of 20,000 virtual MCI patients with (intervention strategy) and without (control strategy) relying on CSF, from a health-care sector perspective and with a 5-year time horizon.
Results:
Adding the CSF test improved the accuracy of prognosis by 11%. This resulted in an average QALY gain of 0.046 and € 432 additional costs per patient, representing an incremental cost-effectiveness ratio of € 9,416.
Conclusion:
The results show the potential of CSF biomarkers in current practice from a health-economics perspective. This result was, however, marked by a high degree of uncertainty, and empirical research is required into the impact of a prognosis on worrying, false-positive/negative prognosis, and stigmatization.
PrinceM, GuerchetM, PrinaM (2015) The Epidemiology and Impact of Dementia: Current State and Future Trends, World Health Organization, Geneva.
2.
PrinceM, WimoA, GuerchetM, AliG, WUY, PrinaM (2015) World Alzheimer Report 2015 The Global Impact of Dementia. Alzheimer’s Disease International, London.
3.
HortJ, O’BrienJT, GainottiG, PirttilaT, PopescuBO, RektorovaI, SorbiS, ScheltensP, EFNS Scientist Panel on Dementia (2010) EFNS guidelines for the diagnosis and management of Alzheimer’s disease. Eur J Neurol17, 1236–1248.
4.
JackCR, AlbertMS, KnopmanDS, McKhannGM, SperlingRA, CarrilloMC, ThiesB, PhelpsCH (2011) Introduction to the recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement7, 257–262.
5.
DuboisB, FeldmanHH, JacovaC, DekoskyST, Barberger-GateauP, CummingsJ, DelacourteA, GalaskoD, GauthierS, JichaG, MeguroK, O’brienJ, PasquierF, RobertP, RossorM, SallowayS, SternY, VisserPJ, ScheltensP (2007) Research criteria for the diagnosis of Alzheimer’s disease: Revising the NINCDS-ADRDA criteria. Lancet Neurol6, 734–746.
AlbertMS, DeKoskyST, DicksonD, DuboisB, FeldmanHH, FoxNC, GamstA, HoltzmanDM, JagustWJ, PetersenRC, SnyderPJ, CarrilloMC, ThiesB, PhelpsCH (2011) The diagnosis of mild cognitive impairment due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement7, 270–279.
8.
VosSJB, VerheyF, FrölichL, KornhuberJ, WiltfangJ, MaierW, PetersO, RütherE, NobiliF, MorbelliS, FrisoniGB, DrzezgaA, DidicM, van BerckelBNM, SimmonsA, SoininenH, KłoszewskaI, MecocciP, TsolakiM, VellasB, LovestoneS, MuscioC, HerukkaS-K, SalmonE, BastinC, WallinA, NordlundA, de MendonçaA, SilvaD, SantanaI, LemosR, EngelborghsS, Vander MusseleS, Alzheimer’s Disease Neuroimaging Initiative, Freund-LeviY, WallinÅK, HampelH, van der FlierW, ScheltensP, VisserPJ (2015) Prevalence and prognosis ofAlzheimer’s disease at the mild cognitive impairment stage. Brain138, 1327–1338.
9.
Ferrante di RuffanoL, HydeCJ, McCafferyKJ, BossuytPMM, DeeksJJ (2012) Assessing the value of diagnostic tests: A framework for designing and evaluating trials. BMJ344, e686.
10.
LijmerJG, LeeflangM, BossuytPMM (2009) Proposals for a phased evaluation of medical tests. Med Decis Mak29, E13–E21.
11.
MeijsAP, ClaassenJAHR, RikkertMGMO, SchalkBWM, MeulenbroekO, KesselsRPC, MelisRJF (2015) How does additional diagnostic testing influence the initial diagnosis in patients with cognitive complaints in a memory clinic setting?Age Ageing44, 72–77.
12.
HandelsRLH, JooreMA, VosSJB, AaltenP, RamakersIHGB, RikkertMO, ScheltensP, JansenWJ, VisserP-J, van BerckelBMN, van DomburgP, SmidM, HoffE, HoogmoedJ, BouwmanF, ClaassenJ, LeentjensAFG, WolfsCAG, SeverensJL, VerheyFRJ (2016) Added prognostic value of cerebrospinal fluid biomarkers in predicting decline in memory clinic patients in a prospective cohort. J Alzheimers Dis52, 875–885.
13.
DuitsFH, PrinsND, LemstraAW, PijnenburgYAL, BouwmanFH, TeunissenCE, ScheltensP, van der FlierWM (2015) Diagnostic impact of CSF biomarkers for Alzheimer’s disease in a tertiary memory clinic. Alzheimers Dement11, 523–532.
14.
DuboisB, PadovaniA, ScheltensP, RossiA, Dell’AgnelloG (2015) Timely diagnosis for Alzheimer’s disease: A literature review on benefits and challenges. J Alzheimers Dis49, 617–631.
15.
RobinsonL, GemskiA, AbleyC, BondJ, KeadyJ, CampbellS, SamsiK, ManthorpeJ (2011) The transition to dementia–individual and family experiences of receiving a diagnosis: A review. Int Psychogeriatr23, 1026–1043.
16.
PaulsenJS, NanceM, KimJ-I, CarlozziNE, PanegyresPK, ErwinC, GohA, McCuskerE, WilliamsJK (2013) A review of quality of life after predictive testing for and earlier identification of neurodegenerative diseases. Prog Neurobiol110, 2–28.
17.
Valcárcel-NazcoC, Perestelo-PérezL, MolinuevoJL, MarJ, CastillaI, Serrano-AguilarP (2014) Cost-effectiveness of the use of biomarkers in cerebrospinal fluid for Alzheimer’s disease. J Alzheimers Dis42, 777–788.
18.
HandelsRLH, JooreMA, Tran-DuyA, WimoA, WolfsCAG, VerheyFRJ, SeverensJL (2015) Early cost-utility analysis of general and cerebrospinal fluid-specific Alzheimer’s disease biomarkers for hypothetical disease-modifying treatment decision in mild cognitive impairment. Alzheimers Dement11, 896–905.
19.
SköldungerA, JohnellK, WinbladB, WimoA (2013) Mortality and treatment costs have a great impact on the cost-effectiveness of disease modifying drugs in Alzheimer’s disease. Curr Alzheimer Res10, 207–216.
20.
BiasuttiM, DufourN, FerroudC, DabW, TemimeL (2012) Cost-effectiveness of magnetic resonance imaging with a new contrast agent for the early diagnosis of Alzheimer’s disease. PLoS One7, e35559.
21.
GuoS, GetsiosD, HernandezL, ChoK, LawlerE, AltincatalA, LanesS, BlankenburgM (2012) Florbetaben PET in the early diagnosis of Alzheimer’s disease: A discrete event simulation to explore its potential value and key data gaps. Int J Alzheimers Dis2012, 548157.
22.
BarnettJH, LewisL, BlackwellAD, TaylorM (2014) Early intervention in Alzheimer’s disease: A health economic study of the effects of diagnostic timing. BMC Neurol14, 101.
23.
IJzermanMJ, SteutenLMG (2011) Early assessment of medical technologies to inform product development and market access. Appl Health Econ Health Policy9, 331–347.
24.
HandelsR, VosS, KrambergerM, JelicV, BlennowK, van BuchemM, van der FlierW, Freund-LeviY, HampelH, Olde RikkertM, OleksikA, PirtosekZ, ScheltensP, SoininenH, TeunissenC, TsolakiM, WallinA, WinbladB, VerheyF, VisserP (2017) Predicting progression to dementia in persons with mild cognitive impairment using cerebrospinal fluid markers. Alzheimers Dement13, 903–912.
25.
DuitsFH, Martinez-LageP, PaquetC, EngelborghsS, LleóA, HausnerL, MolinuevoJL, StomrudE, FarottiL, RamakersIHGB, TsolakiM, SkarsgårdC, ÅstrandR, WallinA, VyhnalekM, Holmber-ClausenM, ForlenzaO V., GhezziL, IngelssonM, HoffEI, RoksG, deMendonçaA, PapmaJM, IzagirreA, TagaM, StruyfsH, AlcoleaDA, FrölichL, BalasaM, MinthonL, TwiskJWR, PerssonS, ZetterbergH, van der FlierWM, TeunissenCE, ScheltensP, BlennowK (2016) Performance and complications of lumbar puncture inmemory clinics: Results of the multicenter lumbar puncturefeasibility study. Alzheimers Dement12, 154–163.
26.
WimoA, ReligaD, SpångbergK, EdlundA-K, WinbladB, EriksdotterM (2013) Costs of diagnosing dementia: Results fromSveDem, the Swedish Dementia Registry. Int J GeriatrPsychiatry28, 1039–1044.
ZwaapJ, KniesS, van der MeijdenC, StaalP, van der HeidenL (2015) Kosteneffectiviteit in de praktijk. The Hague.
29.
van GiessenA, MoonsKGM, de WitGA, VerschurenWMM, BoerJMA, KoffijbergH (2015) Tailoring the implementation of new biomarkers based on their added predictive value in subgroups of individuals. PLoS One10, e0114020.
30.
CoastJ, FlynnTN, NatarajanL, SprostonK, LewisJ, LouviereJJ, PetersTJ (2008) Valuing the ICECAP capability index for older people. Soc Sci Med67, 874–882.
